What is the risk of intracranial bleeding during anti-VEGF therapy?

@article{Carden2008WhatIT,
  title={What is the risk of intracranial bleeding during anti-VEGF therapy?},
  author={Craig P. Carden and James M. G. Larkin and Mark Andrew Rosenthal},
  journal={Neuro-oncology},
  year={2008},
  volume={10 4},
  pages={624-30}
}
Vascular endothelial growth factor (VEGF) is a key mediator of physiological and pathological angiogenesis. All solid tumors are dependent on pathological angiogenesis, and anti-VEGF therapy has demonstrated clinical benefit in breast, colorectal, non-small-cell lung, and renal carcinomas. Central nervous system metastases are common in many of these tumor types. An increased risk of bleeding has been reported with anti-VEGF therapy, but the risk of intracranial bleeding is unknown with this… CONTINUE READING